<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48770">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02139228</url>
  </required_header>
  <id_info>
    <org_study_id>V37_07E2</org_study_id>
    <nct_id>NCT02139228</nct_id>
  </id_info>
  <brief_title>Persistency Study After Hib-CRM197 or Hib-TT Vaccines in Chinese Children</brief_title>
  <official_title>A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2 + 1 Dose Series of Either CRM197- Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-conjugate Haemophilus Influenzae Type b Vaccine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the persistency of immune response against Haemophilus influenzae type b by
      assessing anti-PRP antibody levels in children vaccinated with either Hib-CRM197 or Hib-TT
      booster vaccine approximately 4 years before.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Ratio of anti-PRP antibody geometric mean concentrations (GMCs), approximately four years after booster vaccination by vaccine group.</measure>
    <time_frame>day 1 (four years after booster vaccination received in V37_07E1 study)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess anti- PRP antibodies persistency in children participating in previous V37_07E1 trial, approximately 4 years after booster vaccination with either Hib-CRM197 or Hib-TT.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Haemophilus Influenzae Type b Invasive Disease</condition>
  <condition>Gram-negative Invasive Infections</condition>
  <arm_group>
    <arm_group_label>Group 1 Hib-CRM197</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccine Groups in V37_07E1 study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Hib-TT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccine Groups in V37_07E1 study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hib-CRM197 in V37_07E1</intervention_name>
    <description>no vaccine administered in V37_07E2 study</description>
    <arm_group_label>Group 1 Hib-CRM197</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hib-TT in V37_07E1 study</intervention_name>
    <description>no vaccine administered in V37_07E2 study</description>
    <arm_group_label>Group 2: Hib-TT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. children previously enrolled in V37_07E1 study and who received the appropriate
             vaccination.

          2. children whose parent(s) or legal guardian(s) have given written consent after the
             nature of the study has been explained according to local regulatory requirements.

        Exclusion Criteria:

          1. any confirmed or suspected current immunosuppressive or immunodeficient condition
             since the end of V37_07E1 study, based on medical history and physical examination
             (no laboratory testing required).

          2. treatment with corticosteroids or other immunosuppressive/immunostimulant drugs as
             defined below: i) chronic use of oral and parenteral immunosuppressants (&gt;/= 15 days
             of use) or other immune-modifying drugs within 60 days prior to the blood sampling
             (short term usage of topic, inhaled and/or intranasal corticosteroids is allowed) ii)
             receipt of immunostimulants within 60 days prior to Visit 1

          3. administration of immunoglobulines and/or any blood products up to 3 months before
             enrollment.

          4. use of any investigational or non-registered product (drug or vaccine) within 30 days
             preceding the blood sampling.

          5. any condition, which, in the opinion of the investigator, might be a contraindication
             to the execution of the blood draw.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Drug Information Services</last_name>
    <phone>+1 800 244 7668</phone>
  </overall_contact>
  <location>
    <facility>
      <name>DingXing CDC</name>
      <address>
        <city>Dingxing</city>
        <state>Hebei</state>
        <zip>050021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuliang Zhao</last_name>
      <phone>+86 15931052736</phone>
      <email>yuliang_zh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilus influenzae type b</keyword>
  <keyword>persistency</keyword>
  <keyword>children</keyword>
  <keyword>CRM197</keyword>
  <keyword>anti-PRP antibody</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Haemophilus Infections</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
